Search research articles
Contact Us
Filters
Showing results (641-650 of 658) with videos related to
Page
of 66
Sort By:
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Blood
|
November 19, 2011
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure
Michael R DeBaun, Sharada A Sarnaik, Mark J Rodeghier, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Blood Advances
|
August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Zachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
The New England Journal of Medicine
|
August 21, 2014
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia
Michael R DeBaun, Mae Gordon, Robert C McKinstry, et al.
Blood Cancer Journal
|
March 24, 2026
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study
Matthew Hamby, Brian L Egleston, Zachary A K Frosch, et al.
Blood Advances
|
May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Rahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Science (New York, N.Y.)
|
February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Journal of Global Health
|
July 27, 2023
Anxiety, concerns and COVID-19: Cross-country perspectives from families and individuals with neurodevelopmental conditions
Vassilis Sideropoulos, Jo Van Herwegen, Ben Meuleman, et al.
Page
of 66
Search research articles
Search
Showing results (641-650 of 658) with videos related to
Sort By:
Page
of 66
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Blood
|
November 19, 2011
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure
Michael R DeBaun, Sharada A Sarnaik, Mark J Rodeghier, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Blood Advances
|
August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Zachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
The New England Journal of Medicine
|
August 21, 2014
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia
Michael R DeBaun, Mae Gordon, Robert C McKinstry, et al.
Blood Cancer Journal
|
March 24, 2026
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study
Matthew Hamby, Brian L Egleston, Zachary A K Frosch, et al.
Blood Advances
|
May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Rahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Science (New York, N.Y.)
|
February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Journal of Global Health
|
July 27, 2023
Anxiety, concerns and COVID-19: Cross-country perspectives from families and individuals with neurodevelopmental conditions
Vassilis Sideropoulos, Jo Van Herwegen, Ben Meuleman, et al.
Page
of 66